Saqib Iqbal; Director, Investor Relations; SI-BONE Inc. Laura Francis; Chief Executive Officer, Director; SI-BONE Inc. Anshul Maheshwari; Chief Financial Officer; SI ...

as well as implantable bone products such as iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and ...

Over 1,400 active U.S. physicians with 300 physicians added in the quarter, representing 27.3% growth CMS FY 2026 proposed ...

The company expects a full-year gross margin of 78% and aims for positive adjusted EBITDA in 2025. Si-Bone is also preparing for the Q1 2026 launch of a new SI joint fusion solution, which could ...

SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, sacropelvic fixation and pelvic trauma.

Si-Bone is also preparing for the Q1 2026 launch of a new SI joint fusion solution, which could further bolster its market position.